Dr. Stephanie D. Pointer
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Morehouse School of Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 295
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: Morehouse School of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
TN license 52077 -
Internal Medicine Physician
TN license 52077 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tristar Stonecrest Medical Center Smyrna, TN
Medical groups
- Nashville Gastroenterology and Hepatology (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 295
- Services billed
- 624
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 179 | 107 |
| New patient office or other outpatient visit, 45-59 minutes | 101 | 101 |
| Established patient office or other outpatient visit, 20-29 minutes | 79 | 64 |
| Complete ultrasound scan of abdomen | 36 | 33 |
| New patient office or other outpatient visit, 30-44 minutes | 32 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Nashville, TN | 49 |
| Pantoprazole Sodium Other prescribers in Nashville, TN | 35 |
| Linzess (linaclotide) Other prescribers in Nashville, TN | 32 |
| Trulance (plecanatide) | 26 |
| Dicyclomine Hcl Other prescribers in Nashville, TN | 15 |
| Colestipol Hcl Other prescribers in Nashville, TN | 14 |
| Omeprazole Other prescribers in Nashville, TN | 14 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Nashville, TN | 12 |
| Dexlansoprazole Dr (dexlansoprazole) Other prescribers in Nashville, TN | 12 |
| Ocaliva (obeticholic acid) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 93 payments worth $3,834 in total to this clinician.
| Genentech USA, Inc. | $2,000 |
|---|---|
| Janssen Biotech, Inc. | $352 |
| AbbVie Inc. | $286 |
| Takeda Pharmaceuticals U.S.A., Inc. | $184 |
| Gilead Sciences, Inc. | $149 |
| Lilly USA, LLC | $108 |
| Pfizer Inc. | $90.27 |
| Genzyme Corporation | $88.08 |
| Consulting Fee | $2,000 |
|---|---|
| Food and Beverage | $1,720 |
| Education | $114 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Dec 9, 2025 | Consulting Fee | $2,000 |
| Janssen Biotech, Inc. Jul 30, 2025 | Education TREMFYA · Immunology · in-kind | $76.99 |
| Janssen Pharmaceuticals, Inc Jul 22, 2025 | Education in-kind | $36.96 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 7 companies. The companies reported $346,146 in research payments for these studies, mostly to the institutions running them.
- A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
Sanofi US Services Inc. · Active, not recruiting · NCT06557772 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie Inc. · Active, not recruiting · NCT06063967 - A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
F. Hoffmann-la Roche AG - A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
AbbVie Inc. · Active, not recruiting · NCT06880744 - UC P3: Double-Blind Treat Straight Through
Genentech, Inc. - EoE-201
Phathom Pharmaceuticals, Inc. - A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
Genentech, Inc. - Single-patient expanded access protocol for tradipitant in a single patient with gastroparesis
Vanda Pharmaceuticals Inc. - Evaluating the safety and efficacy of tradipitant vs. placebo in idiopathic and diabetic gastroparesis
Vanda Pharmaceuticals Inc. - An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
E.r. Squibb & Sons, L.l.c. · Terminated · NCT05369832
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.